SCH772984

目录号:S7101

SCH772984 Chemical Structure

Molecular Weight(MW): 587.67

SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。

规格 价格 库存 购买数量  
RMB 2210.07 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • 293T cells were transfected with Flag-WT-FBW7. Thirty hours post transfection, cells were pretreated with MG132 and various MEK/ERK inhibitors overnight before harvesting. FBW7 phosphorylation status was examined by immunoblot analysis after immunoprecipitation.

    Cell Research, 2015, 25: 561-573. SCH772984 purchased from Selleck.

    K562 cells were exposed to ERK inhibitor SCH772984 (1 uM, 2 uM, 5 uM) for 48 h. Apoptosis was analyzed by Annexin V-APC labeling.

    Leuk Lymphoma 2014 1, 8. SCH772984 purchased from Selleck.

  • ERK1/2 influences the effects of TGF-β1 on Cdk5 and Bax in PC12 cells. A. Original western blot showing the level of Cdk5 and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. B. Arithmetic means ± SEM (n = 4) of Cdk5 protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. C. Original western blot showing the level of Bax and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) for 2 h. D. Arithmetic means ± SEM (n = 4) of Bax protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) for 2 h. **(p < 0.01), ***(p < 0.001) indicate statistically significant difference.

    Biochem Biophys Res Commun, 2017, 485(4):775-781. SCH772984 purchased from Selleck.

产品安全说明书

ERK抑制剂选择性比较

生物活性

产品描述 SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。
特性 SCH772984不直接抑制MEK1, MEK2, BRAF, 或 CRAF酶活性。
靶点
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
体外研究

SCH772984是新型,选择性,ATP竞争性的ERK1/2抑制剂。SCH772984抑制ERK底物p90核糖体S6激酶(T359/S363 磷酸化-RSK)的磷酸化,这种作用存在剂量依赖性。SCH772984也能抑制ERK自身活化环中残基的磷酸化。SCH772984分别抑制约88%和49%BRAF突变型或RAS-突变型肿瘤细胞系,EC50值<500 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 NWTHbIxXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3WxcGlEPTB;MD6yOEBvVQ>? NVXnfld6OjV|NUC5N|E>
WM-266-4 M1;RS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJyIH7N M1z2d|I{PjF2OEm4
UACC-62 NYWyTHlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTNyIH7N M2LYU|I{PjF2OEm4
Colo-205 NGfNUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;OXZdDUUN3ME2zOkBvVQ>? MYGyN|YyPDh7OB?=
SK-Mel-1 MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;BO|JKSzVyPUO3JI5O NE[3e4wzOzZzNEi5PC=>
WiDr MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXHTWM2OD1|OTDuUS=> MmjZNlM3OTR6OUi=
M14 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPtNY9KSzVyPUS3JI5O MUCyN|YyPDh7OB?=
HT-29 MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf1ToNKSzVyPUWwJI5O Ml7qNlM3OTR6OUi=
8505C NITVeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTVyIH7N MU[yN|YyPDh7OB?=
HT-144 NH3ZcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTZyIH7N M3rXbVI{PjF2OEm4
SK-Mel-5 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nud2lEPTB;Nk[gcm0> MmDHNlM3OTR6OUi=
A375-SM NEOzOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TKUGlEPTB;N{Wgcm0> MmLTNlM3OTR6OUi=
SK-Mel-28 M3:1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjmbZBwUUN3ME24OUBvVQ>? M4H0dFI{PjF2OEm4
LOX M3v5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonwTWM2OD1zMECgcm0> NH3Ub48zOzZzNEi5PC=>
SK-Mel-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDqWWVbUUN3ME2xNVghdk1? MVSyN|YyPDh7OB?=
K1 NID2fHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml71TWM2OD1zM{Cgcm0> M3vDflI{PjF2OEm4
Hs-695T NX24VpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYr2NFVzUUN3ME2xOlUhdk1? NYfK[2VvOjN4MUS4PVg>
BHT-101 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DmfGlEPTB;M{CwJI5O M4fu[lI{PjF2OEm4
RPMI-7951 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN2NDDuUS=> M1PXXlI{PjF2OEm4
A2058 NXnFV5pZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33aeWlEPTB;M{[wJI5O MljxNlM3OTR6OUi=
SK-Hep-1 NXvPbGNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF2MkKgcm0> NFW5OHUzOzZzNEi5PC=>
A673 M1vFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37HbGlEPTB;M{CwNUBvVQ>? MWOyN|YyPDh7OB?=
DBTRG-05MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNyMEGgcm0> NHjjXGQzOzZzNEi5PC=>
SW-626 M3npU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTkTWM2OD1|MzDuUS=> MXmyN|YyPDh7OB?=
LoVo NFPxXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonmTWM2OD12NzDuUS=> NWrWUnlqOjN4MUS4PVg>
MiaPaCa MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTV|IH7N NGDScFEzOzZzNEi5PC=>
SW-620 NXPVRWs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPhOFhXUUN3ME2xNFQhdk1? MnLWNlM3OTR6OUi=
CAPAN-1 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTYOYhKSzVyPUGwOEBvVQ>? NH\WelczOzZzNEi5PC=>
SW-527 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjRTWM2OD1zMkGgcm0> NY[wV|FGOjN4MUS4PVg>
HCT-116 MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPpNpRRUUN3ME2xNlghdk1? M{fMSVI{PjF2OEm4
SW-480 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy0fpdKSzVyPUG2OUBvVQ>? NFmwU|kzOzZzNEi5PC=>
HPAC NEm5cmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF5MDDuUS=> NIO0V3kzOzZzNEi5PC=>
OVCAR-5 NH30bndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG0d5FKSzVyPUKwPEBvVQ>? NVfDd|lqOjN4MUS4PVg>
AsPc-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzXRYlmUUN3ME2yO|Ahdk1? NF7vbVgzOzZzNEi5PC=>
A549 NX3CPHlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTN{NjDuUS=> NULnPG1UOjN4MUS4PVg>
SNU-1 M{jy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPBbFlKSzVyPUO1OEBvVQ>? MWmyN|YyPDh7OB?=
HOP62 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojrTWM2OD14N{[gcm0> NVniXoRyOjN4MUS4PVg>
H23 NFP2T4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW5TWM2OD1zMECwJI5O M3:3dVI{PjF2OEm4
MB-231 NF3BOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLpTWM2OD1zMECwJI5O MnvPNlM3OTR6OUi=
SU.86.86 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\nTWM2OD1zMECxJI5O M4m0TVI{PjF2OEm4
CFPAC-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWzSHkyUUN3ME2xNFAyKG6P M4rrUFI{PjF2OEm4
A427 M2XFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1i2e2lEPTB;MUSzN{BvVQ>? MnvJNlM3OTR6OUi=
MDAH-2774 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELrN4ZKSzVyPUK2OVchdk1? M4PsUVI{PjF2OEm4
NCI-H157 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M124e2lEPTB;M{CwNEBvVQ>? MY[yN|YyPDh7OB?=
HTB-177 NWWwcW5PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNyMECgcm0> MlWxNlM3OTR6OUi=
UM-UC-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvkTWM2OD1|MECxJI5O NXnUcHZnOjN4MUS4PVg>
HCT-8 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[ydWlEPTB;M{CwNUBvVQ>? NYnrVYNwOjN4MUS4PVg>
Panc-1 NVHBWo9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPoVJlLUUN3ME2zNFAyKG6P M{PNd|I{PjF2OEm4
DLD-1 NX3BUnVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXzTWM2OD1|MECxJI5O NFPNb4ozOzZzNEi5PC=>
HCT-15 M2fqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTsTWM2OD1|MECxJI5O NH7kVIkzOzZzNEi5PC=>
HL-60 NUXNNlRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XnV2lEPTB;M{Cgcm0> Mn7QNlM3OTR6OUi=
SK-Mel-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTN2IH7N M2LVeFI{PjF2OEm4
RD M3zWd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVflN|dGUUN3ME2xNlMhdk1? Mne2NlM3OTR6OUi=
HT-1197 NHv1VlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjiTppKSzVyPUOxOkBvVQ>? NVXKeFZkOjN4MUS4PVg>
Molt-3 M13nbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;KPGlEPTB;NkCwJI5O M2rnbFI{PjF2OEm4
PA-1 M2L0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jzdWlEPTB;MUCwNUBvVQ>? NU\FZph7OjN4MUS4PVg>
Molt-4 NUnUcmxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYq2[WxIUUN3ME2zNFAyKG6P M4[5W|I{PjF2OEm4
NCI-H292 MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TLVmlEPTB;OUCgcm0> M3HN[|I{PjF2OEm4
A2780 Mn\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi1SWJKSzVyPUG0N{BvVQ>? NUe4dZF{OjN4MUS4PVg>
IGROV-1 NWmyeWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr5TWM2OD1zNE[gcm0> M2rhW|I{PjF2OEm4
SK-N-SH MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zWOWlEPTB;MUWwJI5O NYDlN2JGOjN4MUS4PVg>
N-87 NX3JZoZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXvcXBKSzVyPUOwO{BvVQ>? MW[yN|YyPDh7OB?=
H322 MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m4dWlEPTB;M{K1JI5O M{\J[lI{PjF2OEm4
H716 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTN|NDDuUS=> M3W2VlI{PjF2OEm4
TT M2HYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmewTWM2OD12ME[gcm0> M3iyRVI{PjF2OEm4
Caki-1 NEjFO|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHpfZNKSzVyPUS1NEBvVQ>? MV[yN|YyPDh7OB?=
5637 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j3SWlEPTB;NkGwJI5O MYOyN|YyPDh7OB?=
MB-453 M{jvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX2TWM2OD14N{Kgcm0> MkHkNlM3OTR6OUi=
RT-4 NYHNXFFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYL0bnAyUUN3ME24NVAhdk1? NFjNRWQzOzZzNEi5PC=>
HOP92 NHq5XYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX6T29ZUUN3ME24NlAhdk1? MkDuNlM3OTR6OUi=
KG-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HBXmlEPTB;OUCwJI5O NYfvXWhxOjN4MUS4PVg>
Hs-294T NHPS[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPjemdKSzVyPUm0OUBvVQ>? NI\vWWwzOzZzNEi5PC=>
SF-539 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTFyMECgcm0> NELTXlczOzZzNEi5PC=>
U-251 NGHtdHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHOfVVKSzVyPUGwNFAhdk1? Ml7ZNlM3OTR6OUi=
MB-468 M2LZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTFyMECgcm0> MnWxNlM3OTR6OUi=
HS746T M1\pcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLZUVIzUUN3ME2xNFAxKG6P MnvtNlM3OTR6OUi=
SCABER MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nmb2lEPTB;MUCwNEBvVQ>? M4nPclI{PjF2OEm4
MCF-7 NYjaNpk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;2N2lEPTB;MUCwNUBvVQ>? M3j1NVI{PjF2OEm4
CHL-1 MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrVTWM2OD1zNE[wJI5O NXLWe5h2OjN4MUS4PVg>
U87MG NYnERmhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nQeWlEPTB;MkCwNEBvVQ>? MkjuNlM3OTR6OUi=
SJCRH30 NIDYSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXaTWM2OD1{MECyJI5O MkX4NlM3OTR6OUi=
ES-2 M4\tNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD5XmN[UUN3ME2yOlU6KG6P MVeyN|YyPDh7OB?=
HT-1376 M2W5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfORpRKSzVyPUK4NFAhdk1? M4jpNlI{PjF2OEm4
A172 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\jeYRKSzVyPUOwNFAhdk1? MWKyN|YyPDh7OB?=
769P NIK4NodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTNyMECgcm0> NX3ZZ4xROjN4MUS4PVg>
NCI-H520 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fsVmlEPTB;M{CwNEBvVQ>? MW[yN|YyPDh7OB?=
DU145 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q0VWlEPTB;M{CwNEBvVQ>? M2C0S|I{PjF2OEm4
K562 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVKyN49zUUN3ME2zNFAxKG6P MnXhNlM3OTR6OUi=
U-937 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDFTWM2OD1|MECwJI5O M{K0b|I{PjF2OEm4
A204 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD6RYxiUUN3ME2zNFAyKG6P NHS4fYwzOzZzNEi5PC=>
DAOY M2rrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvCVI91UUN3ME2zNFAyKG6P MkXjNlM3OTR6OUi=
SF-268 MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTGOIpKSzVyPUOwNFEhdk1? MWCyN|YyPDh7OB?=
SF-295 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLJUWlKSzVyPUOwNFEhdk1? M1fjTVI{PjF2OEm4
SNB-19 NF\MV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXwTol1UUN3ME2zNFAyKG6P NUnGVVk5OjN4MUS4PVg>
SNB-75 M2[xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rQbWlEPTB;M{CwNUBvVQ>? MVGyN|YyPDh7OB?=
U373-MG M3ezd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHexPZlKSzVyPUOwNFEhdk1? MlvBNlM3OTR6OUi=
786-O MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK4fFZkUUN3ME2zNFAyKG6P NV\xO|htOjN4MUS4PVg>
A498 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoP1TWM2OD1|MECxJI5O Mm\kNlM3OTR6OUi=
ACHN M4LiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTNyMEGgcm0> M{[5clI{PjF2OEm4
EKVX MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF20bXlKSzVyPUOwNFEhdk1? NInO[mczOzZzNEi5PC=>
H226 M1rPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\nd4tKSzVyPUOwNFEhdk1? MW[yN|YyPDh7OB?=
H522 NX\Obnl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTNyMEGgcm0> M33hVlI{PjF2OEm4
HeLa MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nacWlEPTB;M{CwNUBvVQ>? MVSyN|YyPDh7OB?=
SK-OV-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWGwTnRZUUN3ME2zNFAyKG6P M1u3bFI{PjF2OEm4
Ln Cap NXnjTXpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTNyMEGgcm0> NGrNZY4zOzZzNEi5PC=>
PC3 NWnVNWQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzOVXBKSzVyPUOwNFEhdk1? NXnu[oFvOjN4MUS4PVg>
SNU-16 NGrKSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rQRWlEPTB;M{CwNUBvVQ>? NEnRfIUzOzZzNEi5PC=>
FTC-133 MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj6[oVKSzVyPUOwNFEhdk1? NHyxbFMzOzZzNEi5PC=>
Ro82-W-1 NF3FZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j3WWlEPTB;M{CwNUBvVQ>? NFj1doUzOzZzNEi5PC=>
Daudi NYrG[5J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;lW5NKSzVyPUOwNFEhdk1? MojONlM3OTR6OUi=
Jijoye NYG5d2ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPNTWM2OD1|MECxJI5O NFv2fm4zOzZzNEi5PC=>
Jurkat NUSyfJlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle3TWM2OD1|MECxJI5O M1[zVlI{PjF2OEm4
J-82 NFjVOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7EV3FuUUN3ME2zNFAyKG6P MlnSNlM3OTR6OUi=
TCC-SUP M4P3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPNcolSUUN3ME2zNFAyKG6P NEXN[HAzOzZzNEi5PC=>
BT-474 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTNyMEGgcm0> MlTtNlM3OTR6OUi=
ZR-75-1 NF7hT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjtTWM2OD1|MECxJI5O M{jiRVI{PjF2OEm4

... Click to View More Cell Line Experimental Data

体内研究 SCH772984按耐受剂量处理移植瘤模型,诱导肿瘤衰退。SCH772984作用于抗BRAF或MEK抑制剂的模型,有效抑制MAPK信号和细胞增殖。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

ERK2 IMAP 酶实验:

SCH772984作用于纯化的ERK2或ERK1,按一式两份进行8点稀释曲线。酶添加到实验板中。与化合物温育,然后加入底物肽和ATP溶液中。384孔板中每孔加入14μl稀释的酶(每组反应含0.3ng活性ERK2)。实验板轻轻震荡混合试剂,然后在室温下温育45分钟。加入60μl of IMAP 结合溶液 (IMAP珠在1X结合缓冲液中按1:2200稀释)终止反应。实验板在室温下再温育0.5小时,使磷酸肽与IMAP珠完全结合。然后在 LJL分析仪上读数。
细胞实验:

[1]

+ 展开
  • Cell lines: BRAF突变型或 RAS突变型肿瘤系
  • Concentrations: ~10 μM
  • Incubation Time: 5 天
  • Method:

    在96孔板中进行细胞增殖实验,细胞按每孔 4,000个的密度接种。接种24小时后,使用DMSO处理细胞,9点IC50稀释 (0.001-10 μM) ,DMSO终浓度为1%。使用ViaLight发光试剂盒5天后,测定存活力。细胞系存活力检测中,使用SCH772984处理细胞4天,然后进行CellTiterGlo发光细胞活力检测。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 裸鼠
  • Formulation: --
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
0.6mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 587.67
化学式

C33H33N9O2

CAS号 942183-80-4
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • 回答:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

ERK Signaling Pathway Map

Tags: 购买SCH772984 | SCH772984供应商 | 采购SCH772984 | SCH772984价格 | SCH772984生产 | 订购SCH772984 | SCH772984代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID